Welcome to our dedicated page for Solana Co SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solana Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solana Co's regulatory disclosures and financial reporting.
Helius Medical Technologies (HSDT) received a Schedule 13G/A filed by CVI Investments, Inc. and Heights Capital Management, Inc. The filers state they collectively hold 0 shares, representing 0% of the Class A common stock, and that ownership is at or below the 5% threshold. Heights Capital is identified as the investment manager to CVI and may be deemed to have voting and dispositive power over CVI's shares, while each party disclaims beneficial ownership except for any pecuniary interest.
The filing references a previously filed limited power of attorney and a joint filing agreement and contains no disclosure of an acquisition, disposition, or group control.
Helius Medical Technologies, Inc. (NASDAQ: HSDT) filed an 8-K (Item 8.01) announcing an updated Prospectus Supplement that refreshes its June 2023 at-the-market (ATM) Sales Agreement with Roth Capital Partners. The supplement permits the Company to sell up to US$25 million of registered Class A common stock on Nasdaq or other permitted venues.
• Shares will be issued under the existing S-3 Registration Statement (File No. 333-270433) and qualify as Rule 415(a)(4) “at-the-market offerings.”
• Sales may occur at prevailing or negotiated market prices.
• Use of proceeds: working capital and general corporate purposes, including commercialization and R&D.
• Honigman LLP provided the accompanying legal opinion (Exhibit 5.1) with related consent (Exhibit 23.1).
- The filing does not state how many shares have been sold to date or provide financial metrics.
- No changes to the underlying Sales Agreement terms were disclosed; the update primarily refreshes the prospectus amount.
This 8-K does not constitute an offer to sell securities; it merely notifies investors of the updated prospectus that enables future capital raises via the established ATM facility.